Risk of triple-class virological failure in children with HIV: a retrospective cohort study - Wikidata - wikimedia - TriplyDB

Risk of triple-class virological failure in children with HIV: a retrospective cohort study

Risk of triple-class virological failure in children with HIV: a retrospective cohort study

http://www.wikidata.org/entity/Q34997180

about

Dolutegravir-based antiretroviral therapy in a severely overweight child with a multidrug-resistant human immunodeficiency virus infection. A case report and review High drug resistance prevalence among vertically HIV-infected patients transferred from pediatric care to adult units in Spain From transmission to transition: lessons learnt from the Thai paediatric antiretroviral programme Clinical Determinants of HIV-1B Between-Host Evolution and their Association with Drug Resistance in Pediatric Patients Long-term virological outcome in children on antiretroviral therapy in the UK and Ireland.Therapeutic DNA vaccination of vertically HIV-infected children: report of the first pediatric randomised trial (PEDVAC)Suboptimal immune reconstitution in vertically HIV infected children: a view on how HIV replication and timing of HAART initiation can impact on T and B-cell compartment Addressing the socio-development needs of adolescents living with HIV/AIDS in Nigeria: a call for action Changing Trends in Complications and Mortality Rates Among US Youth and Young Adults With HIV Infection in the Era of Combination Antiretroviral Therapy.High rates of virological failure and drug resistance in perinatally HIV-1-infected children and adolescents receiving lifelong antiretroviral therapy in routine clinics in Togo.Development of antiretroviral resistance in children with HIV in low- and middle-income countries The changing epidemiology of the global paediatric HIV epidemic: keeping track of perinatally HIV-infected adolescents.Second-line protease inhibitor-based HAART after failing non-nucleoside reverse transcriptase inhibitor-based regimens in Asian HIV-infected children.Phenotypic Coreceptor Tropism in Perinatally HIV-infected Youth Failing Antiretroviral Therapy.Immediate antiretroviral therapy in young HIV-infected children: benefits and risks.Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe Drug resistance in the HIV-1-infected paediatric population worldwide: a systematic review.Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes.Antiretroviral use in Italian children with perinatal HIV infection over a 14-year period.The EPIICAL project: an emerging global collaboration to investigate immunotherapeutic strategies in HIV-infected children.Tackling virological failure in HIV-infected children living in Africa.Universal antiretroviral therapy for HIV-infected children: a review of the benefits and risks to consider during implementation.Growing up with perinatal HIV: changes in clinical outcomes before and after transfer to adult care in the UK.Pretreatment HIV drug resistance results in virological failure and accumulation of additional resistance mutations in Ugandan children.Children and young people with perinatal HIV in Europe: epidemiological situation in 2014 and implications for the future.Impact of disease, drug and patient adherence on the effectiveness of antiviral therapy in pediatric HIV.Efficacy and tolerance of dolutegravir-based combined ART in perinatally HIV-1-infected adolescents: a French multicentre retrospective study.Young adults HIV-1 infected by vertical transmission in southern Brazil - Clinical, demographic, and virological features.Virological response and resistances over 12 months among HIV-infected children less than two years receiving first-line lopinavir/ritonavir-based antiretroviral therapy in Cote d'Ivoire and Burkina Faso: the MONOD ANRS 12206 cohort.Cohort Profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord.Special considerations concerning the use of antiretroviral drugs in children.Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life.Pathogenesis of infections in HIV-infected individuals: insights from primary immunodeficiencies.HIV-1 drug resistance prevalence, drug susceptibility and variant characterization in the Jacobi Medical Center paediatric cohort, Bronx, NY, USA.When to start, what to start and other treatment controversies in pediatric HIV infection.The case for viral load testing in adolescents in resource-limited settings.Dolutegravir plus abacavir/lamivudine works in adolescents, but size matters.International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK Simulation Modeling and Metamodeling to Inform National and International HIV Policies for Children and Adolescents Clinical, virological and immunological features of HIV-positive children internationally adopted in France from 2005-2015

P2860

Q28086985-74E526C8-6F27-45A1-A2C5-63B7001A48B2 Q28484394-F30418A8-DBFF-460B-A4CE-BEDF23572962 Q28539321-816D1C3A-E945-48A8-A3D2-9F071BAE7C20 Q28554672-3D986DE2-6BFA-4935-80A5-8A72095811A1 Q34410947-3743C41E-C686-4494-A61A-CD6114CF40D8 Q35060232-EF7A218B-F0E0-4344-BF7E-0C1FE769AFE0 Q35895763-EB3916B6-94A4-4029-9C65-E36249F4FDA4 Q36297708-AF1D07E6-A5BE-4CCB-8189-D5A0A47141BB Q36311433-4471F069-DEE0-440D-89B1-EC6D1AC6D5B5 Q36849698-001C6380-EC16-46F3-88B3-D1B10DF8F021 Q36852631-7026F205-D04D-4BD4-9F64-9B4C0EF26CBD Q36941665-095ACA14-891E-4364-B7BF-8F60D6A5268F Q37025153-56C58D98-BB8F-47AB-A592-4688D5548819 Q37182431-7A845282-44D2-4CA2-9A7B-CBBFE7D6ABEB Q37403284-BE809018-1EA6-48A3-B13D-41E43F25B019 Q37631931-9CA52182-CEED-4FAE-B497-AD9645A886AE Q38208721-3BC091F1-DCEE-4A55-B72F-2F631504A8FC Q38428663-44EFADC9-11A4-43AC-8D34-8D4C0A4C43DF Q38433613-870663E3-3865-4662-AA4A-728DEEBE4F61 Q38505356-CBF71E82-55BE-4212-8440-80CF5C6847D2 Q38552894-7BADC46E-2CC3-4BE8-992F-01BC0E410C42 Q38660444-6273C4F6-34C6-4FB3-B0C0-07F7010645BF Q38771852-184F6847-74DD-48CF-8C53-5B44C6AD4965 Q38849814-EE80D097-2FFD-4CB6-8529-C575C50C13BA Q38893689-BACC3BF2-7D8C-4BEB-8FF2-6D1C0D77E502 Q39064765-CBEF9719-B67D-47F2-8605-41D5EF6334C4 Q39080586-7E8C1B9D-8901-446C-9437-C4861ED080C6 Q40167132-8165C83B-8B47-4CF5-961F-C53D35B4CB90 Q40223405-E4B3ED85-1479-4A2E-A763-3BD708B65F1F Q40444741-6BF9885E-744A-422C-94B3-ACB8A7A0E5D2 Q40535139-F9530A5D-37F6-4F14-8878-9CD8EBC4C507 Q41505058-B65219C0-BE6F-4A51-A9E6-D26AC4E95564 Q41989467-F55FBABC-5EEC-4497-8B51-A98D5D69D22B Q42263579-51859ADD-8589-4966-86EB-EE05BDCFF49A Q44986291-B02C4165-49A3-4F76-B0D7-9573ED951938 Q46391416-80C47955-72D6-4002-ADA9-3B4AD70E90BA Q47178545-0E64D3CB-F137-48AC-A953-B93EF859B76B Q56762706-2DA25166-ADD9-4ED9-9615-DA8A5795D87C Q57169257-2854F663-96AB-453D-9428-829F4208AB52 Q59126542-CD11CC22-8260-4FC4-9848-FDD868DF1178

P2860

Risk of triple-class virological failure in children with HIV: a retrospective cohort study

http://www.wikidata.org/entity/Q34997180

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Risk of triple-class virologic ...... : a retrospective cohort study

@ast

Risk of triple-class virologic ...... : a retrospective cohort study

@en

Risk of triple-class virologic ...... : a retrospective cohort study

@nl

type

label

Risk of triple-class virologic ...... : a retrospective cohort study

@ast

Risk of triple-class virologic ...... : a retrospective cohort study

@en

Risk of triple-class virologic ...... : a retrospective cohort study

@nl

prefLabel

Risk of triple-class virologic ...... : a retrospective cohort study

@ast

Risk of triple-class virologic ...... : a retrospective cohort study

@en

Risk of triple-class virologic ...... : a retrospective cohort study

@nl

P1433

Q34997180-1C652B17-C803-4C0F-A244-0B51513F7E75

P1476

Q34997180-BE896AD7-FB61-495A-93D3-EC449D8AA4D0

P2093

Q34997180-0A910C40-E499-436B-AF97-D4C1E75A1E02

Q34997180-3D41D695-89A5-4BE1-9A6C-318E1B628212

Q34997180-51FD8F93-3E7A-49B0-8FD5-08D679333F33

Q34997180-64CEC9E3-3A31-4BDC-B3A5-3E5ADDB3DE8E

Q34997180-6F8BBE88-4A6C-4308-97E7-B6C7E71372E7

Q34997180-79578F7E-4955-41FB-ADD8-C8DA34D2F3F2

Q34997180-910A6F6A-81E6-4A00-8A0F-F98153CBC01F

Q34997180-A49C37D7-A065-4806-84D6-53A4CB55FB5E

Q34997180-E8CFE192-4BCB-40A8-8F37-6978579B5AD6

P2860

Q34997180-0B0837CD-8890-4F79-90B3-D4C8CC79170B

Q34997180-2772DDE1-89A4-401F-B9F7-2891A0A32641

Q34997180-2B7DFFE5-CDB7-4109-8543-5926499AA37F

Q34997180-44865267-8EC5-4CC2-BD35-64937B4E2E2E

Q34997180-538D69F2-E347-4B25-B438-F989B0663C0A

Q34997180-595125C1-8746-4B89-A7AF-3C9F14C23B09

Q34997180-5F7EA22C-15A3-4A3B-B37F-B4D2FA539511

Q34997180-63C5494F-1A14-4C34-89B3-34FD7238D792

Q34997180-65ECEB89-1946-497A-9FFA-FA431D8A74AA

Q34997180-71541C0D-E6DD-4109-97BA-2099EACF92FB

P304

Q34997180-36B794BA-02D0-42FD-8F13-392A67486230

P31

Q34997180-096812C1-44EE-4F02-9CC6-9CAFBB9ED89D

P356

Q34997180-C3A7A4EC-C9F0-4E0D-8359-5EB3BF00630C

P407

Q34997180-ABF267B1-20C1-4FB0-8AA3-FFC5892233DD

P433

Q34997180-EF48A797-41F7-425F-AAA2-91575D21BA0D

P478

Q34997180-674B5FC5-B5A1-4D4C-89E4-718535BBE0EB

P50

Q34997180-5A1EE4A1-AD56-4E32-8EF5-12C8279D9724

Q34997180-6425D213-2559-43B5-AE10-8C53C5884D4D

Q34997180-70E2E4ED-E0B0-4144-B58E-71FFFAB9AAB7

Q34997180-8CFFB1F4-B687-429B-AEB9-4D267E719B14

Q34997180-8E6C990A-E423-4990-B3E6-FBB9EC7C9A0B

Q34997180-A14C20A1-4247-4104-806E-0D11353AEA6F

Q34997180-AFC85AC5-55F5-4142-9E2A-DF86FADDD943

Q34997180-C377C06E-9CE5-4434-9F2D-2677C1B54173

Q34997180-C87022FF-850E-4EA7-9814-CD64179AF2F4

Q34997180-C8D8C382-82C0-4065-A774-263D986EB287

P577

Q34997180-A0848869-8E33-41D0-92F3-52B1A2CF4413

P5875

Q34997180-BD38E3CF-C6BB-4C07-B47A-63410AF5B043

P698

Q34997180-EE99D8F1-0B9B-4597-95DC-85BA5E06A8F4

P921

Q34997180-2EAB8887-042E-47BA-8CA1-5C00783DF2BD

P932

Q34997180-4D48B087-1F17-45B5-AB71-0776B8621083

P356

S0140-6736(11)60208-0

P1433

P1476

Risk of triple-class virologic ...... : a retrospective cohort study

@en

P2093

Andrew Phillips

http://www.w3.org/2001/XMLSchema#string

Céline Colin

http://www.w3.org/2001/XMLSchema#string

Hannah Castro

http://www.w3.org/2001/XMLSchema#string

Jesper Grarup

http://www.w3.org/2001/XMLSchema#string

Jesper Kjaer

http://www.w3.org/2001/XMLSchema#string

Jose T Ramos

http://www.w3.org/2001/XMLSchema#string

Josiane Warsawski

http://www.w3.org/2001/XMLSchema#string

Karina Butler

http://www.w3.org/2001/XMLSchema#string

Pursuing Later Treatment Optio ...... gical Research Europe (COHERE)

http://www.w3.org/2001/XMLSchema#string

P2860

HIV cohort collaborations: proposal for harmonization of data exchange.

Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era

Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry.

Determinants of virological response to antiretroviral therapy: implications for long-term strategies.

Early antiretroviral therapy and mortality among HIV-infected infants

Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997-2005: cohort study.

Adherence-resistance relationships to combination HIV antiretroviral therapy.

First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.

Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years

Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis.

P304

1580-1587

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0140-6736(11)60208-0

http://www.w3.org/2001/XMLSchema#string

P407

P433

9777

http://www.w3.org/2001/XMLSchema#string

P478

377

http://www.w3.org/2001/XMLSchema#string

P50

Geneviève Chêne

Dominique Costagliola

Rebecca Lodwick

Antoni Noguera-Julian

P577

2011-04-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51068647

http://www.w3.org/2001/XMLSchema#string

P698

21511330

http://www.w3.org/2001/XMLSchema#string

P921

P932

3099443

http://www.w3.org/2001/XMLSchema#string